Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Rare diseases stories

Nov 16, 2026

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.

Nov 16, 2026·3 sources
00
Nov 13, 2026

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sources
00
Nov 10, 2026

FDA approves Merck KGaA's pimicotinib for tenosynovial giant cell tumor

The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.

Nov 10, 2026·3 sources
00
Nov 5, 2026

Alethio Therapeutics raises $90M Series A for rare blood cancer antibody

Oxford spinout Alethio Therapeutics secured $90 million in Series A funding to advance an antibody treatment for myeloproliferative neoplasms, a group of rare blood cancers.

Nov 5, 2026·2 sources
00
Nov 4, 2026

AstraZeneca made $10 billion offer for obesity drugmaker Rhythm Pharmaceuticals

AstraZeneca made a $10 billion takeover offer for Rhythm Pharmaceuticals, which specializes in treatments for metabolic conditions and severe obesity, according to sources familiar with the matter.

Nov 4, 2026·2 sources
00
Nov 3, 2026

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 2026·2 sources
00
Nov 1, 2026

Setara Biosciences launches with $90M for rare disease drug development

Setara Biosciences has started operations with $90 million in funding and a lead drug candidate already in clinical trials for Charcot-Marie-Tooth disease type 2C and overactive bladder.

Nov 1, 2026·4 sources
00
Oct 30, 2026

FDA approves Inovio's Voceryq for recurrent respiratory papillomatosis

The U.S. Food and Drug Administration has approved Inovio Pharmaceuticals' treatment Voceryq for recurrent respiratory papillomatosis, a rare throat disease. The approval sent Inovio's shares surging.

Oct 30, 2026·4 sources
00
Oct 29, 2026

Stem cell transplants show 60% progression-free survival at 10 years for severe systemic sclerosis

An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.

Oct 29, 2026·3 sources
00

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

California biotech Dren Bio secured $350 million in funding to advance its lead blood cancer therapy toward a potential market launch by the end of 2027.

Oct 29, 2026·3 sources
00
Oct 28, 2026

FDA releases guidance for individualized gene editing therapies

The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.

Oct 28, 2026·2 sources
00
Oct 20, 2026

Katherine Screws' 3-year wait for intestine transplant highlights complexity of US organ system

Katherine Screws, a Phoenix woman whose small intestine was destroyed in a car crash, waited three years for an intestine transplant while dependent on IV nutrition. She was among just 88 people in the U.S. to receive an intestine transplant last year, illustrating the challenges and complexity of the organ transplant system for rare procedures.

Oct 20, 2026·4 sources
00
Oct 14, 2026

FDA launches comprehensive review of rare disease drug approval process

The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.

Oct 14, 2026·5 sources
00

Arizona man died from pneumonic plague after contact with sick cats

A man in Arizona died from pneumonic plague last year after having contact with sick cats, according to a recently published report. Pneumonic plague cases are extremely rare in the United States, though plague cases do occasionally occur.

Oct 14, 2026·6 sources
00
Oct 8, 2026

Endeavor BioMedicines' taladegib meets primary endpoint in phase 2b trial for idiopathic pulmonary fibrosis

Endeavor BioMedicines announced that its WHISTLE-PF phase 2b trial of taladegib met its primary endpoint, demonstrating statistically significant improvement in lung function (ppFVC) compared to placebo in patients with IPF. The company claims the drug has potential to reverse disease course, unlike current therapies that only slow progression.

Oct 8, 2026·2 sources
00
Oct 5, 2026

Epicrispr reports updated trial data for epigenetic editing treatment in FSHD muscular dystrophy

Epicrispr Biotechnologies presented encouraging updated findings from testing of its epigenetic editing treatment for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disease. The data builds the case for the company's therapeutic approach to treating the condition.

Oct 5, 2026·2 sources
00
Oct 3, 2026

Z-basivarsen shows sustained benefits in myotonic dystrophy type 1 trial

An investigational drug, z-basivarsen, demonstrated sustained improvements in myotonia, motor function, and strength in patients with myotonic dystrophy type 1, according to analysis from the ACHIEVE trial. The findings suggest potential therapeutic benefits for this genetic neuromuscular disorder.

Oct 3, 2026·2 sources
00
Sep 24, 2026

Kyverna Therapeutics reports one-year durability data for autoimmune cell therapy

Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.

Sep 24, 2026·4 sources
00
Sep 21, 2026

EMA committee recommends approval of glepaglutide for short-bowel syndrome

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending Zeydovio (glepaglutide) for marketing authorization in treating short-bowel syndrome. The GLP-2 analog is developed by Zealand Pharma A/S.

Sep 21, 2026·1 source
00
Sep 17, 2026

FDA approves Ultragenyx's Fayuvi, first gene therapy for Sanfilippo syndrome type A

The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.

Sep 17, 2026·4 sources
00
Sep 8, 2026

BrainChild Bio raises $116M series A for pediatric brain cancer CAR-T therapy

BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.

Sep 8, 2026·3 sources
00
Aug 28, 2026

FDA approves Mimrylo, first-of-its-kind drug for polycythemia vera

The U.S. Food and Drug Administration approved Mimrylo (rusfertide), developed by Takeda Pharmaceutical and Protagonist Therapeutics, as the first drug of its kind to treat polycythemia vera, a rare blood disorder that causes overproduction of red blood cells.

Aug 28, 2026·3 sources
00
Aug 18, 2026

Leo Pharma acquires worldwide rights to dersimelagon for up to $435M

Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.

Aug 18, 2026·2 sources
00
Aug 13, 2026

PTC Therapeutics acquires Sangamo's Fabry disease gene therapy for $211M in bankruptcy auction

PTC Therapeutics won the bankruptcy auction for Sangamo Therapeutics' gene therapy assets with a $211 million bid. Sangamo filed for Chapter 11 bankruptcy in June after failing to find strategic alternatives.

Aug 13, 2026·2 sources
00
Aug 10, 2026

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00

Silence Therapeutics reports positive Phase 2 trial results for divesiran in rare blood cancer

Silence Therapeutics announced that its Phase 2 SANRECO trial of divesiran met its primary endpoint in patients with polycythemia vera, a rare blood cancer, with data showing the treatment stabilized red blood cell levels and reduced phlebotomies to 0.2 per patient over 36 weeks. The company's stock rallied significantly on the news.

Aug 10, 2026·9 sources
00
Aug 6, 2026

Intellia Therapeutics Reports Positive Phase 3 Results for HAE Treatment, Plans 2027 U.S. Launch

Intellia Therapeutics announced second quarter 2026 financial results alongside positive Phase 3 clinical data for lonvo-z in hereditary angioedema (HAE), with FDA biologics license application acceptance anticipated in late 2026 and U.S. commercial launch planned for first half of 2027.

Aug 6, 2026·2 sources
00

Tarsus Pharmaceuticals to Acquire Alkeus for Up to $800M, Gaining Late-Stage Stargardt Disease Drug

Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.

Aug 6, 2026·5 sources
00
Aug 4, 2026

Merck's anti-TL1A antibody shows mixed Phase 2 results in hidradenitis suppurativa and lung disease

Merck's anti-TL1A antibody from its 2023 Prometheus Biosciences acquisition delivered positive mid-stage results in hidradenitis suppurativa but failed to meet endpoints in a rare lung disease trial. The company disclosed the mixed Phase 2 results alongside its second-quarter earnings.

Aug 4, 2026·2 sources
00
Jul 30, 2026

UK Authorises Myqorzo and NICE Recommends It for Obstructive Hypertrophic Cardiomyopathy

Britain's medicines regulator has approved Cytokinetics' drug for a rare heart condition, with the National Institute for Health and Care Excellence (NICE) recommending it for NHS reimbursement, making it accessible to approximately 6,600 patients in the UK.

Jul 30, 2026·1 source
00
Jul 28, 2026

Novel interventional approach shows success in treating hepatic myelopathy, rare liver disease complication

Researchers have developed a new interventional treatment for hepatic myelopathy, a rare neurological complication of chronic liver disease that previously could only be cured through liver transplantation.

Jul 28, 2026·1 source
00
Jul 27, 2026

AstraZeneca reports mixed late-stage trial results with Ultomiris failure and Claudin 18.2 ADC success

AstraZeneca announced Monday that its rare disease drug Ultomiris failed a late-stage trial for blood vessel complications following stem cell transplants, while a separate trial of its Claudin 18.2-targeting antibody-drug conjugate in stomach cancer succeeded. The Ultomiris setback adds to concerns about the drugmaker's pipeline following a series of setbacks this year.

Jul 27, 2026
00
Jul 24, 2026

11-Year-Old London Girl Becomes First UK Patient to Receive Gene Therapy for Rare Sight-Robbing Condition

Catherine L'Estrange from North Acton became the first patient in the UK and second in the world to receive groundbreaking gene therapy for Bardet-Biedl syndrome, a rare condition that progressively causes blindness in children. The treatment, performed at St Helier Hospital in March, involves injecting healthy copies of a gene directly into the eye.

Jul 24, 2026·5 sources
00
Jul 21, 2026

Broad Institute, Boston Children's Hospital, and Jackson Laboratory Launch $160 Million Center for Rare Disease Gene Therapies

Three major research institutions announced the creation of the Center for Therapeutic Genetics, a nonprofit collaboration aimed at developing standardized genetic medicines, including base and prime editing, for rare and ultra-rare diseases that currently lack treatments.

Jul 21, 2026·9 sources
00

Personalized Antisense Therapy Shows Promise in Treating Rare Genetic Epilepsy in Two Patients

Two patients with SCN2A-related developmental epileptic encephalopathy experienced reductions in seizure frequency after receiving individualized allele-selective antisense oligonucleotides. The treatments were well tolerated, with no ASO-related serious adverse events reported in two parallel single-patient studies published in Nature Medicine.

Jul 21, 2026·1 source
00
Jun 16, 2026

Northern California resident becomes fourth person ever diagnosed with rare Rickettsia lanei tick-borne illness

A Northern California resident was hospitalized this spring after being confirmed as the fourth-ever person diagnosed with an extremely rare tick-borne disease caused by Rickettsia lanei bacteria, which produces symptoms similar to Rocky Mountain spotted fever. State health officials are warning residents to take precautions against ticks following the diagnosis.

Jun 16, 2026·4 sources
00
May 26, 2026

New York confirms first case of rare tick-borne Bourbon virus in Long Island man

Michael Larkin of Shirley, Long Island, survived New York's first confirmed case of Bourbon virus after being bitten by ticks while landscaping in May 2021. The rare tick-borne illness caused severe symptoms including high fevers, headaches, and rash, requiring a five-day hospitalization.

May 26, 2026·4 sources
00

Top claims

  • ▪Eli Lilly agreed to acquire Wellesley, Massachusetts-based biotech startup Calytrix Bio Inc. for up to $1.5 billion
  • ▪Eli Lilly has pursued company acquisitions throughout 2026 to expand into oncology, hematology, and autoimmune diseases beyond its blockbuster diabetes and weight-loss franchise
  • ▪Existing therapies for myeloproliferative neoplasms include blood transfusions and JAK inhibitor drugs such as Incyte's Jakafi, which manage disease symptoms rather than targeting underlying mutations

People involved

Catherine L'Estrange

Subtopics

Drug Policy, Pricing & Approval20Clinical trials14Drug Approval and Clinical Trials14Drug development10Pharmaceutical Industry9Biotechnology7Cancer & Oncology7Gene therapy7Mergers & acquisitions (M&A)7Pharma6FDA drug approval5Hematology & Blood Cancers5Biotech startup4Clinical Genomics & Genetics4Clinical evaluation3Clinical Trial Design & Evaluation3Hematology3Mergers and acquisitions3Orphan drug designation3Rare genetic diseases3Venture capital funding3Autoimmune disease2Autoimmune disease treatments2Cancer Treatment & Therapies2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories